Alexion Pharmaceuticals, confirmed that Deborah Dunsire, MD has been appointed to its Board of Directors as a new independent director. Dr. Dunsire served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the transformation of the company into a biotechnology industry leader. Prior to Millennium, Dr. Dunsire led the Novartis North America Oncology Business, Dr. Dunsire currently serves as President and Chief Executive Officer of Xtuit Pharmaceuticals, Inc., a privately held biopharmaceutical company developing novel therapeutics. Dr. Dunsire also serves on the boards of Xtuit and Ultragenyx Pharmaceutical, Inc., and previously served on the boards of Takeda Pharmaceuticals, Allergan, Inc. and FORUM Pharmaceuticals, Inc. She received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.
David Brennan, Chairman of the Board, commented, “We are delighted to welcome Deborah to Alexion’s Board of Directors. Her experience will be highly valuable to our board as we continue to position Alexion to deliver long-term growth and sustainable value for our shareholders. Alexion has made excellent progress over the past year, enhancing our corporate governance, refocusing our business strategy and achieving important corporate milestones. We look forward to working with Deborah as we continue to build on our leadership in treating patients with rare diseases.”